TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2019 DA - 2019// TI - Cancer statistics, 2019 JO - CA Cancer J Clin VL - 69 UR - https://doi.org/10.3322/caac.21551 DO - 10.3322/caac.21551 ID - Siegel2019 ER - TY - JOUR AU - Chen, Z. AU - Fillmore, C. M. AU - Hammerman, P. S. AU - Kim, C. F. AU - Wong, K. K. PY - 2014 DA - 2014// TI - Non-small-cell lung cancers: a heterogeneous set of diseases JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3775 DO - 10.1038/nrc3775 ID - Chen2014 ER - TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortettieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Liu, T. C. AU - Jin, X. AU - Wang, Y. AU - Wang, K. PY - 2017 DA - 2017// TI - Role of epidermal growth factor receptor in lung cancer and targeted therapies JO - Am J Cancer Res. VL - 7 ID - Liu2017 ER - TY - JOUR AU - Herbst, R. S. AU - Hong, W. K. PY - 2001 DA - 2001// TI - IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer JO - Expert Opin Biol Ther. VL - 29 UR - https://doi.org/10.1517/14712598.1.4.719 DO - 10.1517/14712598.1.4.719 ID - Herbst2001 ER - TY - JOUR AU - Yoshida, T. AU - Zhang, G. AU - Haura, E. B. PY - 2010 DA - 2010// TI - Targeting epidermal growth factor receptor: central signaling kinase in lung cancer JO - Biochem Pharmacol VL - 80 UR - https://doi.org/10.1016/j.bcp.2010.05.014 DO - 10.1016/j.bcp.2010.05.014 ID - Yoshida2010 ER - TY - JOUR AU - Arkhipov, A. AU - Shan, Y. AU - Das, R. AU - Endres, N. F. AU - Eastwood, M. P. AU - Wemmer, D. E. AU - Kuriyan, J. AU - Shaw, D. E. PY - 2013 DA - 2013// TI - Architecture and membrane interactions of the EGF receptor JO - Cell VL - 152 UR - https://doi.org/10.1016/j.cell.2012.12.030 DO - 10.1016/j.cell.2012.12.030 ID - Arkhipov2013 ER - TY - JOUR AU - Endres, N. F. AU - Das, R. AU - Smith, A. W. AU - Arkhipov, A. AU - Kovacs, E. AU - Huang, Y. AU - Pelton, J. G. AU - Shan, Y. AU - Shaw, D. E. AU - Wemmer, D. E. PY - 2013 DA - 2013// TI - Conformational coupling across the plasma membrane in activation of the EGF receptor JO - Cell VL - 152 UR - https://doi.org/10.1016/j.cell.2012.12.032 DO - 10.1016/j.cell.2012.12.032 ID - Endres2013 ER - TY - JOUR AU - Carcereny, E. AU - Morán, T. AU - Capdevila, L. AU - Cros, S. AU - Vilà, L. AU - Gil, M. D. L. L. AU - Remón, J. AU - Rosell, R. PY - 2015 DA - 2015// TI - The epidermal growth factor receptor (EGRF) in lung cancer JO - Trends Mol Med. VL - 3 ID - Carcereny2015 ER - TY - JOUR AU - Yang, C. S. AU - Wang, Z. Y. PY - 1993 DA - 1993// TI - Tea and cancer JO - J Natl Cancer Inst VL - 85 UR - https://doi.org/10.1093/jnci/85.13.1038 DO - 10.1093/jnci/85.13.1038 ID - Yang1993 ER - TY - JOUR AU - Stoner, G. D. AU - Mukhtar, H. PY - 2010 DA - 2010// TI - Polyphenols as cancer chemopreventive agents JO - J Cell Biochem Suppl VL - 59 UR - https://doi.org/10.1002/jcb.240590822 DO - 10.1002/jcb.240590822 ID - Stoner2010 ER - TY - JOUR AU - Ma, Y. C. AU - Li, C. AU - Gao, F. AU - Xu, Y. AU - Jiang, Z. B. AU - Liu, J. X. AU - Jin, L. Y. PY - 2014 DA - 2014// TI - Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway JO - Oncol Rep VL - 31 UR - https://doi.org/10.3892/or.2013.2933 DO - 10.3892/or.2013.2933 ID - Ma2014 ER - TY - JOUR AU - Liang, Y. C. AU - Lin-Shiau, S. Y. AU - Chen, C. F. AU - Lin, J. K. PY - 1997 DA - 1997// TI - Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells JO - J Cell Biochem VL - 67 UR - https://doi.org/3.0.CO;2-V DO - 3.0.CO;2-V ID - Liang1997 ER - TY - JOUR AU - Baba, S. AU - Osakabe, N. AU - Natsume, M. AU - Muto, Y. AU - Takizawa, T. AU - Terao, J. PY - 2001 DA - 2001// TI - In vivo comparison of the bioavailability of (+)-catechin, (−)-epicatechin and their mixture in orally administered rats JO - J Nutr VL - 131 UR - https://doi.org/10.1093/jn/131.11.2885 DO - 10.1093/jn/131.11.2885 ID - Baba2001 ER - TY - JOUR AU - Er, J. AU - Lippard, S. J. PY - 1999 DA - 1999// TI - Structure, recognition, and processing of cisplatin-DNA adducts JO - Chem Rev VL - 99 ID - Er1999 ER - TY - JOUR AU - Garces, Á. H. AU - Dias, M. S. AU - Paulino, E. AU - Ferreira, C. G. AU - Melo, A. C. PY - 2015 DA - 2015// TI - Treatment of ovarian cancer beyond chemotherapy: are we hitting the target? JO - Cancer Chemother Pharmacol VL - 75 UR - https://doi.org/10.1007/s00280-014-2581-y DO - 10.1007/s00280-014-2581-y ID - Garces2015 ER - TY - JOUR AU - Morris, G. M. AU - Huey, R. AU - Lindstrom, W. AU - Sanner, M. F. AU - Belew, R. K. AU - Goodsell, D. S. AU - Olson, A. J. PY - 2009 DA - 2009// TI - AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility JO - J Comput Chem VL - 30 UR - https://doi.org/10.1002/jcc.21256 DO - 10.1002/jcc.21256 ID - Morris2009 ER - TY - JOUR AU - Czechura, P. AU - Tam, R. Y. AU - Dimitrijevic, E. AU - Ben, R. N. PY - 2008 DA - 2008// TI - The importance of hydration for inhibiting ice recrystallization with C-linked antifreeze glycoproteins JO - J Am Chem Soc VL - 130 UR - https://doi.org/10.1021/ja7103262 DO - 10.1021/ja7103262 ID - Czechura2008 ER - TY - JOUR AU - Zhang, X. AU - Wang, J. AU - Hu, J. M. AU - Huang, Y. W. AU - Wu, X. Y. AU - Zi, C. T. AU - Wang, X. J. AU - Sheng, J. PY - 2016 DA - 2016// TI - Synthesis and biological testing of novel glucosylated epigallocatechin gallate (EGCG) derivatives JO - Molecules VL - 21 UR - https://doi.org/10.3390/molecules21050620 DO - 10.3390/molecules21050620 ID - Zhang2016 ER - TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Ervik, M. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. AU - Parkin, D. M. AU - Forman, D. AU - Bray, F. PY - 2008 DA - 2008// TI - GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 JO - Int J Cancer. VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2008 ER - TY - JOUR AU - Galluzzi, L. AU - Senovilla, L. AU - Vitale, I. AU - Michels, J. AU - Martins, I. AU - Kepp, O. AU - Castedo, M. AU - Kroemer, G. PY - 2012 DA - 2012// TI - Molecular mechanisms of cisplatin resistance JO - Oncogene VL - 31 UR - https://doi.org/10.1038/onc.2011.384 DO - 10.1038/onc.2011.384 ID - Galluzzi2012 ER - TY - JOUR AU - Wang, H. AU - Bian, S. AU - Yang, C. S. PY - 2011 DA - 2011// TI - Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α JO - Carcinogenesis VL - 32 UR - https://doi.org/10.1093/carcin/bgr218 DO - 10.1093/carcin/bgr218 ID - Wang2011 ER - TY - JOUR AU - Li, G. X. AU - Chen, Y. K. AU - Hou, Z. AU - Xiao, H. AU - Jin, H. Y. AU - Lu, G. AU - Lee, M. J. AU - Liu, B. AU - Guan, F. AU - Yang, Z. H. PY - 2010 DA - 2010// TI - Pro-oxidative activities and dose-response relationship of (−)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro JO - Carcinogenesis VL - 31 UR - https://doi.org/10.1093/carcin/bgq039 DO - 10.1093/carcin/bgq039 ID - Li2010 ER - TY - JOUR AU - Jiang, P. AU - Wu, X. AU - Wang, X. AU - Huang, W. AU - Feng, Q. PY - 2016 DA - 2016// TI - NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.9712 DO - 10.18632/oncotarget.9712 ID - Jiang2016 ER - TY - JOUR AU - Wang, C. AU - Wang, W. AU - Wang, C. AU - Tang, Y. AU - Tian, H. PY - 2015 DA - 2015// TI - Combined therapy with EGFR TKI and gambogic acid for overcoming resistance inEGFR-T790M mutant lung cancer JO - Oncol Lett. VL - 10 UR - https://doi.org/10.3892/ol.2015.3599 DO - 10.3892/ol.2015.3599 ID - Wang2015 ER - TY - JOUR AU - Yarden, Y. PY - 2001 DA - 2001// TI - The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities JO - Eur J Cancer VL - 37 UR - https://doi.org/10.1016/S0959-8049(01)00230-1 DO - 10.1016/S0959-8049(01)00230-1 ID - Yarden2001 ER - TY - JOUR AU - Marmor, M. D. AU - Skaria, K. B. AU - Yarden, Y. PY - 2004 DA - 2004// TI - Signal transduction and oncogenesis by ErbB/HER receptors JO - Int J Radiat Oncol Biol Phys VL - 58 UR - https://doi.org/10.1016/j.ijrobp.2003.06.002 DO - 10.1016/j.ijrobp.2003.06.002 ID - Marmor2004 ER - TY - JOUR AU - Reungwetwattana, T. AU - Weroha, S. J. AU - Molina, J. R. PY - 2012 DA - 2012// TI - Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC) JO - Clin Lung Cancer. VL - 13 UR - https://doi.org/10.1016/j.cllc.2011.09.004 DO - 10.1016/j.cllc.2011.09.004 ID - Reungwetwattana2012 ER - TY - JOUR AU - Eberhard, D. A. PY - 2005 DA - 2005// TI - Mutations in the Epidermal Growth Factor Receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.857 DO - 10.1200/JCO.2005.02.857 ID - Eberhard2005 ER - TY - JOUR AU - Tsao, M. S. AU - Sakurada, A. AU - Cutz, J. C. PY - 2005 DA - 2005// TI - Erlotinib in lung cancer—molecular and clinical predictors of outcome JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050736 DO - 10.1056/NEJMoa050736 ID - Tsao2005 ER - TY - JOUR AU - Roberts, P. J. AU - Stinchcombe, T. E. PY - 2013 DA - 2013// TI - KRAS mutation: should we test for it, and does it matter? JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.0454 DO - 10.1200/JCO.2012.43.0454 ID - Roberts2013 ER - TY - JOUR AU - Loriot, Y. AU - Mordant, P. AU - Deutsch, E. PY - 2009 DA - 2009// TI - Are RAS mutations predictive markers of resistance to standard chemotherapy? JO - Nat Rev Clin Oncol. VL - 6 UR - https://doi.org/10.1038/nrclinonc.2009.106 DO - 10.1038/nrclinonc.2009.106 ID - Loriot2009 ER - TY - JOUR AU - Henning, S. M. AU - Choo, J. J. AU - Heber, D. PY - 2008 DA - 2008// TI - Nongallated compared with gallated Flavan-3-ols in green and black tea are more bioavailable JO - J Nutr VL - 138 UR - https://doi.org/10.1093/jn/138.8.1529S DO - 10.1093/jn/138.8.1529S ID - Henning2008 ER -